TScan Therapeutics

TSC-101 Clin1 AML, MDS, ALL; TSC-204 5 efforts RD/Clin1 solid tumors; TSC-200 3 efforts RD/Clin0 solid tumors; TSC-203 2 efforts RD/Clin0 solid tumors; TSC-201 3 efforts RD solid tumors; TSC-202 RD solid tumors; TSC-205 RD solid tumors

TScan Therapeutics is developing T cell receptor engineered T cell therapies (TCR-T) for the treatment of patients with cancer. Novel cancer therapies can be generated by learning from patients that are winning their fight against cancer. TScan is using this approach by analyzing the T cells of patients with exceptional responses to immunotherapy to discover clinically relevant targets and TCRs. With this information, TScan is building their ImmunoBank with the goal of delivering customized multiplexed TCR-T therapies to a wide range of patients with hematologic malignancies and solid tumors. Several of TScan’s lead programs have already entered into clinical stages.

Jobs: